Dr. John Cush RheumNow
1 year 10 months ago
RA Treatment Adherence: Is decision making really shared?
Dr. Jonathan Kay interviews Dr. Cécile Gaujoux-Viala about abstract 0360 at #ACR24.
https://t.co/KwXHutfQko https://t.co/bCVM3JrFEz
Dr. John Cush RheumNow
1 year 10 months ago
Treat-to-Target Improves Fertility in Women with RA
Dr. Richard Conway discusses abstract 1647, presented at #ACR24
https://t.co/vC0CA0lN4M https://t.co/Dfo7iBYwcU
Dr. John Cush RheumNow
1 year 10 months ago
GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis
Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have transformed the treatment landscape for type 2 diabetes and obesity. #ACR24
https://t.co/6QqEH8X2VJ https://t.co/Ch2i9zZYii
Dr. John Cush RheumNow
1 year 10 months ago
ORAL Surveillance - Is Statin Use the Problem/Solution?
The findings from ORAL Surveillance Study have been a dominant conversation at #ACR24, with the seminal findings and subsequent analyses a target of debate.
https://t.co/Nn9KSL4dlv https://t.co/gHPwK35eEd
Randomized controlled trials (RCTs) drive guidelines; guidelines drive clinical practice. Because updated guidelines lag trials by many years and dissemination of guidelines takes additional time, rheumatologists often practice “behind the data.” The 2024 ACR Guidelines for the Management of SLE Nephritis reaffirmed many of our typical practice patterns, including hydroxychloroquine for all, renin/angiotensin blockade, and favoring mycophenolate
Dr. John Cush RheumNow
1 year 10 months ago
#ACR24: What Exactly do JAKs and TYKs Do?
Let me start by confessing something embarrassing: the immune system is just too complex for me to understand. I suspect the onslaught of new drugs with new mechanisms at ACR 2024 may have left many of you feeling similarly.… https://t.co/HkhZJBxDdO https://t.co/xYeSpHS2dD
Dr. John Cush RheumNow
1 year 10 months ago
Addressing CV Risk in RA: Are we doing enough?
The increased risk of cardiovascular disease in patients with rheumatoid arthritis has long been known (1). #ACR24
https://t.co/dajYuK8rpd https://t.co/2Ds3OZEjUX
Managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. Our study analyzed Google search trends for rheumatic disease topics, offering a fascinating glimpse into how online search behavior can reveal patient needs and experiences. This approach, known as "infodemiology," tracks real-time Google Trends data to understand symptom- and
Dr. John Cush RheumNow
1 year 10 months ago
Apremilast Benefits and Risks in PsA
Dr. Akhil Sood discusses abstracts 1466, 2583, 0598 and 2640 discussing the use of apremilast in PsA, presented at #ACR24.
https://t.co/SSEeR9Xt9B https://t.co/cUeSUQoRsO
Dr. John Cush RheumNow
1 year 10 months ago
#ACR24 BEST Abstracts from Day 2
Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty.
https://t.co/9qiPhemEPl https://t.co/uGQEiCcfah
Dr. John Cush RheumNow
1 year 10 months ago
#ACR24 - Day 2 Report
Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.
https://t.co/TEWW0mDyl8 https://t.co/mZuqayonPN
Dr. John Cush RheumNow
1 year 10 months ago
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow
1 year 10 months ago
Shedding Weight and Pain: The Promise of Anti-Obesity Medications in RA
For years, rheumatologists have championed weight loss as a cornerstone of care for patients with rheumatoid arthritis (RA) and obesity. RA is an independent risk factor for cardiovascular disease (CVD), a… https://t.co/iozo0FQFzj https://t.co/93e4nZMHJo
